FOI_7390

Internal Reference Number: FOI_7390

Date Request Received: 21/08/2023 00:00:00

Date Request Replied To: 13/09/2023 00:00:00

This response was sent via: By Email

Request Summary: Dermatological conditions

Request Category: Companies


Question Number 1: How many patients were treated in the last 4 months (April to July 2023) by the dermatology department with each of the following products: • Abrocitinib • Acitretin • Alitretinoin • Azathioprine • Baricitinib • Ciclosporin • Dupilumab • Methotrexate • Mycophenolate mofetil • Pimecrolimus • Phototherapy (UVB or PUVA) • Tacrolimus ointment • Tralokinumab • Upadacitinib

Answer To Question 1: • Abrocitinib 0 • Acitretin 30 • Alitretinoin <5 • Azathioprine <5 • Baricitinib <5 • Ciclosporin 12 • Dupilumab 20 • Methotrexate 27 • Mycophenolate mofetil 0 • Pimecrolimus 16 • Phototherapy (UVB or PUVA) 26 • Tacrolimus ointment 21 • Tralokinumab <5 • Upadacitinib <5

Question Number 2: How many patients were treated by the dermatology department in the previous 4-month period (December 22 - March 23) with Dupixent?

Answer To Question 2: 16

Question Number 3: For patients treated by the dermatology department with Dupilumab in the four months from December 22 to March 2023, could you please tell us: a. How many patients were treated in the subsequent 4-month period (April - July 23) with Dupilumab? b. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following advanced therapies - Abrocitinib, Baricictinib, Tralokinumab and Upadacitinib? c. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following immunosuppressants - Methotrexate, Ciclosporin, Mycophenolate or Azathioprine? d. How many patients were treated in the subsequent 4-month period (April - July 23) with any of the following - Acitretin, Alitretoin, Pimecrolimus or Tacrolimus?

Answer To Question 3: a) 16 b) 0 c) 0 d) 0

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.